|


TEL: +32 16 58 90 45
Fax :+ 32 16 50 90 45
GENTAUR Europe
tel+32 2 732 5688
fax+32 2 732 4414
Av.
de l' Armée 68
B-1040 BRUSSELS
BELGIUM

GENTAUR France
tel 01 43 25
01 50
fax01 43 25
01 60
9, rue
Lagrange
75005 PARIS
FRANCE

GENTAUR Italy
tel 02 36 00
65 93
fax 02 36 00
65 94
20135 MILANO
ITALY

GENTAUR Germany
tel +49 241
6085 13140
fax +49 241
6085 33033
Forckenbeckstraße 6,
D-52074
Aachen
GERMANY
| |
• Simple and sensitive alkaline phosphatase tracers
• 18-month stability of the kit and key reagents
• Quick 2-hour incubation and 1-hour development
• Important assays like:
• cAMP and cGMP for cell signaling
• 8-isoprostane for oxidative injury
• TXB2 and 6-keto PGF1α for thrombosis and hematology
• PGE2, LTB4, LTC4, and cysLT for inflammation/allergy
cAMP EIA Kit 133-16475 385 Euro
Adenosine 3’,5’ cyclic monophosphate (cAMP) is a ubiquitous cellular second
messenger that is a critical component of a signal transduction pathway linking
membrane receptors and their ligands to the activation of internal cellular
enzymatic activity and gene expression. The abundance of cAMP within a given
cell serves as a marker for activation by agonists acting at cell surface.
cGMP EIA Kit 133-16475 385 Euro
Guanosine 3’,5’ cyclic monophosphate (cGMP) is a key intracellular second
messenger molecule which transduces cellular signaling events in response to a
variety of hormones, autacoids, and drugs. The abundance of cGMP within a
given cell serves as a marker for activation by agonists acting through
particulate
guanylate cyclase at the cell surface, or intracellular activation of soluble
guanylate
cyclase by nitric oxide.
Cysteinyl-Leukotriene EIA Kit 133-16462 385 Euro
The leukotrienes (LTs) LTC4, LTD4, and LTE4 are collectively referred to as
cysteinyl-leukotrienes (cysLTs). LTC4 and LTD4 are potent mediators of asthma
and hypersensitivity. They induce bronchoconstriction, increase microvascular
permeability, and are vasoconstrictors of coronary arteries. CysLTs are excreted
in
urine as intact LTE4 (~9-12%) and LTE4 metabolites.
Leukotriene B4 EIA Kit 1333-16464 385 Euro
Leukotriene B4 (LTB4) is a potent mediator of inflammation synthesized from
arachidonic acid by the combined action of 5-lipoxygenase and LTA4 hydrolase. It
stimulates a number of leukocyte functions, including aggregation, stimulation
of
ion fluxes, enhancement of lysosomal enzyme release, superoxide anion
production,
chemotaxis, and chemokinesis.
Leukotriene C4 EIA Kit 1333-17331 385 Euro
Leukotriene C4 (LTC4) is a potent mediator of asthma and hypersensitivity
derived via the 5-lipoxygenase pathway in leukocytes, eosinophils, mast cells,
and macrophages. It induces bronchoconstriction, increases microvascular
permeability, and vasoconstriction of coronary arteries.
Leukotriene E4 EIA Kit 1333-16547 385 Euro
Leukotriene E4 (LTE4) is a product of the 5-lipoxygenase (5-LO) pathway in
activated mast cells, eosinophils, and monocytes. LTA4, the primary 5-LO
metabolite, is converted to LTC4 and sequentially to LTD4 and LTE4 in the host
cell, or by transcellular metabolism in erythrocytes, platelets, or neutrophils.
LTC4
and LTD4 are excreted in urine as intact LTE4 and LTE4 metabolites.
Prostaglandin E2 EIA Kit 1333-16359 385 Euro
Prostaglandin E2 (PGE2) is one of the primary cyclooxygenase (COX) products
of arachidonic acid metabolism and one of the most widely investigated PGs.
Its activity influences inflammation, fertility and parturition, gastric mucosal
integrity, and immune modulation. The effects of PGE2 are transduced by at least
four distinct receptors designated EP1, EP2, EP3, and EP4.
6-keto Prostaglandin F1α EIA Kit 1333-16476 385 Euro
Prostacyclin (Prostaglandin I2; PGI2) is formed from arachidonic acid primarily
by
the vascular endothelium and renal cortex. It is a potent vasodilator and
inhibitor
of platelet aggregation. PGI2 is non-enzymatically hydrated to 6-keto PGF1α
(t1/2
= 2-3 minutes), and then quickly converted to the major metabolite, 2,3-dinor-6-
keto PGF1α (t1/2 = 30 minutes) and excreted in the urine.
Prostaglandin F2α EIA Kit 1333-17333 385 Euro
Prostaglandin F2α (PGF2α) is one of the five primary prostaglandins derived
enzymatically directly from the endoperoxide PGH2 via the cyclooxygenase
(COX) metabolic pathway. The majority of the functional roles ascribed to PGF2α
relate to fertility, pregnancy, and parturition. PGF2α is a potent luteolytic
agent
and uterine stimulant, and is part of the cascade of myometrial stimulants which
induce and sustain labor.
8-iso Prostaglandin F2α EIA Kit 1333-16465 385 Euro
8-isoprostane (8-iso PGF2α) is the most studied member of the isoprostane
family of eicosanoids produced by the random oxidation of tissue phospholipids
by oxygen radicals. 8-iso PGF2α appears in the plasma and urine under normal
conditions and is elevated by oxidative injury.
Thromboxane B2 EIA Kit 1333-16463 385 Euro
Thromboxane A2 (TXA2) is produced from arachidonic acid by many cells and
causes irreversible platelet aggregation and contraction of vascular and
bronchial
smooth muscle. TXA2 is rapidly hydrolyzed non-enzymatically to form TXB2,
which is then quickly metabolized (t1/2 = 5-7 minutes) to urinary metabolites
for
clearance by the kidneys.
Kookaburra Kits
Kookaburra Kits represent an exclusive new small molecule
detection platform developed by Sapphire Bioscience in Sydney,
Australia. Sapphire is looking for growing, energetic young
sales and distribution companies specializing in the health
research sciences to help market this new product line
worldwide. Some of the key attributes of these new kits are:
- Simple and sensitive alkaline phosphatase tracers
- 18 month stability of the kit and key reagents
- Quick 2-hour incubation and development
- Important assays like cAMP and cGMP for cell signaling
- 8-isoprostane for oxidative stress
- TXB2 and 6-keto PGF1α for
thrombosis and hematology
- PGE2, LTB4, LTC4, and
cysLT for inflammation/allergy
| Assay |
Description |
Stability |
Range |
IC50 |
Detection Limit |
Cross-Reactivity |
Dilution |
Incubation Time |
Development Time |
|
Cysteinyl Leukotriene |
The leukotrienes (LTs) LTC4, LTD4,
and LTE4 are collectively referred to as
cysteinyl-leukotrienes (cysLTs). LTC4 and
LTD4 are potent mediators of asthma and
hypersensitivity. They induce bronchoconstriction,
increase microvascular permeability, and are
vasoconstrictors of coronary arteries. CysLTs are
excreted in urine as intact LTE4 (~9-12%)
and LTE4 metabolites.
|
18 months |
4.6-10,000 pg/ml |
83 pg/ml |
20 pg/ml |
|
LTC4
|
100%
|
|
LTD4
|
134%
|
|
LTE4
|
121%
|
|
LTC4 methyl ester
|
32%
|
|
LTB4
|
<0.01%
|
|
Arachidonic acid
|
<0.01%
|
|
Cysteine
|
<0.01%
|
|
Glutathione
|
<0.01%
|
|
LTD4
|
134%
|
|
LTE4
|
121%
|
|
LTC4 methyl ester
|
32%
|
|
3-fold |
2 hours |
60-90 minutes |
|
Thromboxane B2 |
Thromboxane A2 (TXA2) is
produced from arachidonic acid by many cells and
causes irreversible platelet aggregation and
contraction of vascular and bronchial smooth muscle.
TXA2 is rapidly hydrolyzed
non-enzymatically to form TXB2, which is
then quickly metabolized (t1/2 = 5-7 minutes) to
urinary metabolites for clearance by the kidneys.
|
18 months |
15.6-2,000 pg/ml |
150 pg/ml |
40 pg/ml |
|
TXB2
|
100%
|
|
TXB3
|
200%
|
|
2,3-dinor TXB2
|
9.90%
|
|
11-dehydro TXB3
|
0.62%
|
|
PGD2
|
0.53%
|
|
11-dehydro TXB2
|
0.42%
|
|
PGF2α
|
0.25%
|
|
PGF1α
|
0.11%
|
|
PGE2
|
0.09%
|
|
6-keto PGF1α
|
0.08%
|
|
LTB4
|
<0.01%
|
|
2,3-dinor-6-keto PGF1α
|
<0.01%
|
|
13,14-dihydro-15-keto PGF2α
|
<0.01%
|
|
Tetranor PGEM
|
<0.01%
|
|
Tetranor PGFM
|
<0.01%
|
|
2-fold |
2 hours |
60-90 minutes |
|
Leukotriene B4 |
Leukotriene B4 (LTB4) is a
potent mediator of inflammation synthesized from
arachidonic acid by the combined action of
5-lipoxygenase and LTA4 hydrolase. It
stimulates a number of leukocyte functions,
including aggregation, stimulation of ion fluxes,
enhancement of lysosomal enzyme release, superoxide
anion production, chemotaxis, and chemokinesis.
|
18 months |
2.3-5,000 pg/ml |
286 pg/ml |
63 pg/ml |
|
Leukotriene B4
|
100%
|
|
20-hydroxy LTB4
|
2.70%
|
|
5,6-DiHETE
|
0.07%
|
|
Glutathione
|
<0.01%
|
|
20-carboxy LTB4
|
<0.01%
|
|
LTC4
|
<0.01%
|
|
LTD4
|
<0.01%
|
|
19(R)-hydroxy PGB2
|
<0.01%
|
|
2.5-fold |
2 hours |
60-90 minutes |
|
cAMP |
Adenosine 3',5' cyclic monophosphate (cAMP) is a
ubiquitous cellular second messenger that is a
critical component of a signal transduction pathway
linking membrane receptors and their ligands to the
activation of internal cellular enzymatic activity
and gene expression. The abundance of cAMP within a
given cell serves as a marker for activation by
agonists acting at cell surface.
|
18 months |
1.4-3,000 pmol/ml |
54 pg/ml |
8 pg/ml |
|
Acetylated cAMP
|
100%
|
|
cAMP
|
3%
|
|
Dibutyryl cAMP
|
0.80%
|
|
Acetylated cGMP
|
0.05%
|
|
AMP
|
<0.01%
|
|
ATP
|
<0.01%
|
|
cGMP
|
<0.01%
|
|
Acetylated adenosine
|
<0.01%
|
|
Acetylated AMP
|
<0.01%
|
|
Acetylated cytidine
|
<0.01%
|
|
Acetylated guanosine
|
<0.01%
|
|
Acetylated uridine
|
<0.01%
|
|
3-fold |
2 hours |
60-90 minutes |
|
cGMP |
Guanosine 3',5' cyclic monophosphate (cGMP) is a key
intracellular second messenger molecule which
transduces cellular signaling events in response to
a variety of hormones, autacoids and drugs. The
abundance of cGMP within a given cell serves as a
marker for activation by agonists acting through
particulate guanylate cyclase at the cell surface,
or intracellular activation of soluble guanylate
cyclase by nitric oxide.
|
18 months |
0.1-300 pmol/ml |
3.2 pg/ml |
0.7 pg/ml |
|
Acetylated cGMP
|
100%
|
|
cGMP
|
9%
|
|
Dibutyryl cGMP
|
0.80%
|
|
Acetylated cAMP
|
0.05%
|
|
cAMP
|
<0.01%
|
|
AMP
|
<0.01%
|
|
ATP
|
<0.01%
|
|
Acetylated adenosine
|
<0.01%
|
|
Acetylated AMP
|
<0.01%
|
|
Acetylated cytidine
|
<0.01%
|
|
Acetylated guanosine
|
<0.01%
|
|
Acetylated uridine
|
<0.01%
|
|
3-fold |
2 hours |
60-90 minutes |
|
Prostaglandin E2 |
Prostaglandin E2 (PGE2) is one
of the primary cyclooxygenase (COX) products of
arachidonic acid metabolism and one of the most
widely investigated PGs. Its activity influences
inflammation, fertility and parturition, gastric
mucosal integrity, and immune modulation. The
effects of PGE2 are transduced by at
least four distinct receptors designated EP1,
EP2, EP3, and EP4.
|
18 months |
31.3-4,000 pg/ml |
334 pg/ml |
80 pg/ml |
|
PGE2
|
100%
|
|
PGE2 Ethanolamide
|
100%
|
|
PGE3
|
43.00%
|
|
8-iso PGE2
|
37.40%
|
|
PGE1
|
18.70%
|
|
6-keto PGF1α
|
1.00%
|
|
8-iso PGF2α
|
0.25%
|
|
PGA1
|
<0.01%
|
|
PGA2
|
<0.01%
|
|
PGA3
|
<0.01%
|
|
PGB1
|
<0.01%
|
|
PGB2
|
<0.01%
|
|
PGD2
|
<0.01%
|
|
15-keto PGE2
|
<0.01%
|
|
PGF1α
|
<0.01%
|
|
PGF2α
|
<0.01%
|
|
13,14-dihydro-15-keto PGF2α
|
<0.01%
|
|
PGF3α
|
<0.01%
|
|
TXB2
|
<0.01%
|
|
Tetranor PGEM
|
<0.01%
|
|
Tetranor PGFM
|
<0.01%
|
|
2-fold |
2 hours |
60-90 minutes |
|
6-keto Prostaglandin F1α |
Prostacyclin (Prostaglandin I2; PGI2)
is formed from arachidonic acid primarily by the
vascular endothelium and renal cortex. It is a
potent vasodilator and inhibitor of platelet
aggregation. PGI2 is non-enzymatically
hydrated to 6-keto PGF1α (t1/2 = 2-3
minutes), and then quickly converted to the major
metabolite, 2,3-dinor-6-keto PGF1α (t1/2
= 30 minutes) and excreted in the urine.
|
18 months |
2.3-5,000 pg/ml |
222 pg/ml |
22 pg/ml |
|
6-keto PGF1α
|
100%
|
|
6-keto PGE1
|
151%
|
|
PGF1α
|
11%
|
|
2,3-dinor-6-keto PGF1α
|
5%
|
|
13,14-dihydro-15-keto PGF1α
|
3%
|
|
PGE2
|
2%
|
|
6,15-diketo-13,14-dihydro PGF1α
|
2%
|
|
PGF2α
|
0.40%
|
|
TXB2
|
0.05%
|
|
PGD2
|
<0.01%
|
|
Tetranor PGEM
|
<0.01%
|
|
Tetranor PGFM
|
<0.01%
|
|
3-fold |
2 hours |
60-90 minutes |
|
8-Isoprostane |
8-isoprostane (8-iso PGF2α) is
the most studied member of the isoprostane family of
eicosanoids produced by the random oxidation of
tissue phospholipids by oxygen radicals. 8-iso
PGF2α appears in the plasma and urine
under normal conditions and is elevated by oxidative
stress.
|
18 months |
1.4-3,000 pg/ml |
103 pg/ml |
18 pg/ml |
|
8-Isoprostane
|
100%
|
|
8-iso PGF3α
|
20.55%
|
|
2,3-dinor-8-iso PGF2α
|
4.00%
|
|
8-iso PGE2
|
1.84%
|
|
2,3-dinor-8-iso PGF1α
|
1.70%
|
|
PGF1α
|
0.71%
|
|
PGF3α
|
0.66%
|
|
PGE1
|
0.39%
|
|
PGD2
|
0.16%
|
|
6-keto PGF1α
|
0.14%
|
|
PGF2α
|
0.14%
|
|
2,3-dinor-6-keto PGF1α
|
0.09%
|
|
8-iso PGF1β
|
0.08%
|
|
TXB2
|
0.08%
|
|
11-dehydro TXB2
|
0.07%
|
|
11β-PGF2α
|
0.03%
|
|
PGE2
|
0.02%
|
|
8-iso-15(R) PGF2α
|
0.02%
|
|
8,12-epi iPF2α-III
|
0.01%
|
|
iPF2α-VI
|
<0.01%
|
|
8,12-epi iPF2α-VI
|
<0.01%
|
|
13,14-dihydro-15-keto PGF2α
|
<0.01%
|
|
Tetranor PGEM
|
<0.01%
|
|
Tetranor PGFM
|
<0.01%
|
|
3-fold |
2 hours |
60-90 minutes |
|
Leukotriene E4 |
Leukotriene E4 (LTE4) is a
product of the 5-lipoxygenase (5-LO) pathway in
activated mast cells, eosinophils, and monocytes.
LTA4, the primary 5-LO metabolite, is
converted to LTC4 and sequentially to LTD4
and LTE4 in the host cell, or by
transcellular metabolism in erythrocytes, platelets,
or neutrophils. LTC4 and LTD4
are excreted in urine as intact LTE4 and
LTE4 metabolites.
|
18 months |
4.6-10,000 pg/ml |
380 pg/ml |
80 pg/ml |
|
LTE4
|
100%
|
|
LTE5
|
100%
|
|
N-acetyl LTE4
|
20%
|
|
LTC4
|
10%
|
|
LTD4
|
7%
|
|
LTC5
|
2%
|
|
LTD5
|
<0.01%
|
|
Arachidonic acid
|
<0.01%
|
|
Tetranor PGEM
|
<0.01%
|
|
Tetranor PGFM
|
<0.01%
|
|
LTB4
|
<0.01%
|
|
LTB5
|
<0.01%
|
|
3-fold |
2 hours |
60-90 minutes |
|
Prostaglandin F2α |
Prostaglandin F2α (PGF2α) is
one of the five primary prostaglandins derived
enzymatically directly from the endoperoxide PGH2
via the cyclooxygenase (COX) metabolic pathway. The
majority of the functional roles ascribed to PGF2α
relate to fertility, pregnancy, and parturition. PGF2α
is a potent luteolytic agent and uterine stimulant,
and is part of the cascade of myometrial stimulants
which induce and sustain labor.
|
18 months |
1.4-3,000 pg/ml |
104 pg/ml |
16 pg/ml |
|
PGF2α Ethanolamide
|
244%
|
|
PGF2α
|
100%
|
|
PGF1α
|
61%
|
|
PGF3α
|
21%
|
|
20-hydroxy PGF2α
|
5.30%
|
|
PGE2
|
2.60%
|
|
PGD2
|
1.20%
|
|
19(R)-hydroxy PGF2α
|
0.69%
|
|
11β-PGF2α
|
0.03%
|
|
6,15-diketo-13,14-dihydro PGF1α
|
0.02%
|
|
11-dehydro TXB2
|
<0.01%
|
|
3-fold |
2 hours |
60-90 minutes |
|
Leukotriene C4 |
Leukotriene C4 (LTC4) is a
potent mediator of asthma and hypersensitivity
derived via the 5-lipoxygenase pathway in
leukocytes, eosinophils, mast cells, and
macrophages. It induces bronchoconstriction,
increases microvascular permeability, and
vasoconstriction of coronary arteries.
|
18 months |
9.1-20,000 pg/ml |
350 pg/ml |
90 pg/ml |
|
LTC4
|
100%
|
|
LTC5
|
100%
|
|
LTD5
|
48%
|
|
LTD4
|
46%
|
|
N-acetyl LTE4
|
28%
|
|
LTE5
|
7%
|
|
LTE4
|
2%
|
|
Glutathione
|
<0.01%
|
|
LTB4
|
<0.01%
|
|
LTB5
|
<0.01%
|
|
Tetranor PGEM
|
<0.01%
|
|
Tetranor PGFM
|
<0.01%
|
|
3-fold |
2 hours |
60-90 minutes |
|
|